EU panel recommends approval of Corcept's relacorilant for ovarian cancer
Corcept Therapeutics (NASDAQ: CORT) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)

